Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-11

Clinical Trial Update: Trial of CF101 to Treat Patients With Dry Eye Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of CF101 for dry eye disease (keratoconjunctivitis sicca) completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CF101 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Keratoconjunctivitis Sicca | Phase 3 | Status: COMPLETED | Results posted: 2015-03-11